Originally published in the Hartford Courant, this op-ed examines Connecticut's Public Act 26-108 and its implications for psychedelic-assisted therapy, evidence-based healthcare innovation, and patient access.

The U.S. Department of Health and Human Services and the Department of Veterans Affairs have announced a landmark partnership to accelerate research and implementation of rapid-acting mental health treatments for veterans, including psychedelic-assisted therapies. Read the official federal announcement below.

Nearly 5 Million U.S. Veterans Have Used Psilocybin Mushrooms, LSD or MDMA; Veterans' Policy Preferences Differ by Psychedelic Substance

New VA Trial of MDMA Psychedelic for PTSD

Starting July 1, CT medical program using psychedelics opens to the public.

New discoveries are reshaping scientific understanding of psychedelic compounds and their potential role in treating mental health conditions. The Atlantic explores the research driving this rapidly evolving field.

Oregon’s psilocybin services program offers an early case study for states considering how to expand access to psychedelics while maintaining responsible safety protections.

The White House has identified Rep. Andy Barr's Amendment #54 as a model for revising federal hemp regulations. Learn what the proposal would have done, why it never received a House vote, and what comes next for H.R. 8646.

The U.S. Department of Veterans Affairs has launched a new MDMA-assisted therapy clinical trial focused on veterans with PTSD and trauma-related conditions. The initiative reflects growing interest in evidence-based psychedelic-assisted therapies and broader efforts to expand innovative mental health treatment options for veterans and other trauma survivors.

Read the full article

The proposal would create a state initiative for clinical studies involving ibogaine and psilocybin

Read the full order here

Press release: Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to a Qualifying State-issued License in Schedule III, Strengthening Medical Research While Maintaining Strict Federal Controls

Press release: President Trump’s Landmark Order Advances Breakthrough Mental Health Treatments — Delivering New Hope to Veterans

A White House executive order on psychedelics, signed by President Donald Trump on Saturday, aims to speed up research on drugs like psilocybin, MDMA and ibogaine, helping to legitimize an industry that’s long lived largely underground.

Executive Order: Accelerating Medical Treatments for Serious Mental Illness Fact Sheet: President Donald J. Trump is Accelerating Medical Treatments for Serious Mental Illness